Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children
description
Transcript of Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children
![Page 1: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/1.jpg)
Kings Coccidioidomycosis Conference:
Coccidioidomycosis In Infants And Children
Francesca Geertsma, MD
Pediatric Infectious Diseases Consultant
Kaweah Health Care District
Associate Professor Pediatrics, UCSF Fresno
![Page 2: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/2.jpg)
California Counties
![Page 3: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/3.jpg)
15 Year Review of Pediatric Coccidioidomycosis
• IRB approved protocol • Retrospective chart review of all patients
seen at Children’s Hospital with a discharge diagnosis of coccidioidomycosis (cocci) from 1990-2005
• 298 charts reviewed, 199 met study criteria for diagnosis of cocci and had data available for review
F. Geertsma, S. Wollersheim, J. Moua, J. Nolt, M. Birmingham and W. Fletcher
![Page 4: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/4.jpg)
15 Year Review-Continued
• Inclusion criteria – Age 0-18 years at time of initial visit– Diagnosis of cocci by clinical signs/symptoms AND
• Histopathology and/or• Positive culture and/or• Positive serology
• We did not include subjects with diagnosis based on skin testing, only clinical suspicion or screening antibody testing (eg EIA)
![Page 5: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/5.jpg)
![Page 6: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/6.jpg)
![Page 7: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/7.jpg)
Complement Fixation Assay
![Page 8: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/8.jpg)
15 Year Review-Data Collection
• Data extracted from charts including information regarding PE, symptoms, demographics, site of infection, laboratory studies, radiographic studies, treatment, follow-up information, hospitalization, ultimate disposition etc.
• Correlations sought to help define clinical disease in this population
• “fishing trip” descriptive design of study hopefully will provide groundwork for more focused inquiries in the future
![Page 9: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/9.jpg)
All Patients by Siten=199
Pulm80%
Dissem11%
CNS8%
1' Cutaneous1%
![Page 10: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/10.jpg)
Sex Ratio of Study Group
Female43%
Male57%
![Page 11: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/11.jpg)
Age Distribution of Study Group
Inf-Tod13%
Preschool Aged7%
School Aged25%
Adolescent55%
![Page 12: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/12.jpg)
Ethnic Background of Study Groupn=199
Hispanic55%
Non-Hispanic White36%
African American4%
Asian5%
![Page 13: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/13.jpg)
Ethnicity vs SiteHispanic
Pulm78%
Dissem12%
CNS10%
![Page 14: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/14.jpg)
Ethnicity vs SiteNon-Hispanic White
Pulm95%
Dissem0%
CNS5%
![Page 15: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/15.jpg)
Ethnicity vs SiteAfrican American
Pulm42%
Dissem50%
CNS8%
![Page 16: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/16.jpg)
Ethnicity vs SiteAsian
Pulm64%
Dissem18%
CNS18%
![Page 17: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/17.jpg)
15 Year Review- Clinical Characteristics
• Immunsp. 3%• Fever 67%• HA 23%• Wt loss 34%• Dyspnea 16%• Hemoptysis 1.5%• Night sweats 9%
• Rash 31%• Arthralgias 12%• Malaise 26%• Cough 62%• Chest pain 26%• Stiff neck 4%• Alt LOC 3%
![Page 18: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/18.jpg)
15 Year Review- Clinical Characteristics
• Arthritis 2%• Abn Breath sounds 20%• Deceased breath sounds 25%• Abscess or mass 7%• EN 11%• EM 1%• Murmers 3%• Lymphadenopathy 9%• HSM 3%
![Page 19: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/19.jpg)
15 Year Review-AssociationsPE/History
– HA and alt LOC assoc with CNS dz– Lymphadenopathy and HSM assoc with dissem dz– EN assoc with pulm dz– Hispanics, Asians then African Americans seen
with increasing rates of disseminated disease (numbers not large enough for Asians to achieve statistical significance but trend demonstrated)
– African American and Asians more likely to present with a soft tissue mass/abscess than Hispanic or White children
– More likely to see HSM in AA children than others with disseminated disease
![Page 20: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/20.jpg)
15 Year Review-Associations
Imaging
• 18% of cases without dissemination dz had negative chest imaging
• 39% of cases with disseminated cases had negative chest imaging studies
• 44% of cases with CNS disease had negative chest imaging studies
![Page 21: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/21.jpg)
15 Year Review Associations
Associations-laboratories…• Markers
– Differentiate disseminated disease from purely pulmonary dz
• ESR 36 in Pulm vs 45 in DDZ (p<.001)
• Alk phos 165 Pulm 275 DDZ (p<0.001)
![Page 22: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/22.jpg)
15 Year Review-Associations
Complement Fixation Titers-Serum
Pulmonary disease 1:11
Disseminated dz +/-CNS 1:55
P<0.001
![Page 23: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/23.jpg)
MENDOTA
COALINGA
HURON
CORCORAN
AVENAL
Fresno
Tulare
Madera
Kings
Kern
Merced
MariposaStanislaus
San Luis Obispo
PORTERVILLE
TULARE
HANFORDLEMOORE
VISALIA
ARVIN
WASCO
DELANO
TAFT
KERMANFRESNO
Valley Fever Unique Patients1 - 2 Patients3 - 7 Patients8 - 24 Patients
Counties
Study Population by Zip Code
![Page 24: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/24.jpg)
Cocci in Kids…
• Issues to consider– Immune status of infants
– Lack of data regarding use of certain antifungals in children and infants
– Practicality of obtaining certain diagnostic procedures in children and infants
– Difficulty in interpreting serologic studies in young infants due to presence of maternal antibody
![Page 25: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/25.jpg)
Cocci in Kids-Observations
• Common cause for referral to ID clinic and ID inpatient consultation since ~2000– Presentations similar to adult disease except
• “big spleen” disease in preadolescent/adolescents
• Disease in young infants-disseminated but not congenital-often with skin disease
– Well appearing despite high titer disease
– Respond to outpatient oral therapy
![Page 26: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/26.jpg)
Cocci in Kids
• Therapy– Amphotericin B-d
• Well tolerated in infants and young children• Used when large fungal burden suspected/patient very ill systemically
– Lipid associated Ampho B • Used as second line therapy when toxicities encountered with ampho
B-d or with treatment failures– Less comorbidities in our population
– Azoles• Fluconazole
– For patients with less severe disease and CNS disease, also when fungal burden not as significant
![Page 27: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/27.jpg)
Cocci in Kids
• Therapy continued– Azoles
• Itraconazole– Used in skeletal dz– Clinical failure on fluconazole esp with CNS dz– Seem to see HTN with chronic use
• Voriconazole– Increasing experience with this drug
» CNS failures on other azoles» Inability to use parenteral antifungals in patients with severe systemic
disease» Dose we use is up to 11mg/kg orally BID
– Immunomodulation?• IFN
![Page 28: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/28.jpg)
Cocci in Kids
Questions that continue to keep us up at night…– Long term effects of the disease , especially in the young
infants we are seeing?– Long term effects of the treatments we are using on the
developing infant/brain?– Role of Voriconazole?– Role of immunomodulators?– What to do with the cohort of young infants we are seeing
with disseminated disease?• What drugs?• How long?• Are there marker for evaluation “maturity of their immune response?
![Page 29: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/29.jpg)
![Page 30: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/30.jpg)
![Page 31: Kings Coccidioidomycosis Conference: Coccidioidomycosis In Infants And Children](https://reader036.fdocuments.us/reader036/viewer/2022062519/5681502b550346895dbe1a86/html5/thumbnails/31.jpg)